Accuray (ARAY) Stock Overview
Engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ARAY from our risk checks.
ARAY Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Accuray Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.17 |
| 52 Week High | US$2.95 |
| 52 Week Low | US$1.10 |
| Beta | 1.05 |
| 1 Month Change | -30.36% |
| 3 Month Change | -15.83% |
| 1 Year Change | -45.58% |
| 3 Year Change | -48.91% |
| 5 Year Change | -69.53% |
| Change since IPO | -95.89% |
Recent News & Updates
Accuray's Latest Transformation Attempt Could Be Too Little Too Late
Nov 06Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price
Oct 10
Recent updates
Accuray's Latest Transformation Attempt Could Be Too Little Too Late
Nov 06Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price
Oct 10Returns At Accuray (NASDAQ:ARAY) Are On The Way Up
Aug 13Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its Revenues
Jun 28Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price
Apr 04Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price Drop
Mar 11Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth
Jan 18Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
Jan 07Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?
Dec 19Accuray Incorporated: Cheap, But With Caveats
Dec 05Accuray Remains A Perpetual 'Next Year Is Our Year' Story
Aug 18Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues
Aug 13Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop
May 21Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results
May 04Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?
May 03Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp
Apr 07Is Accuray (NASDAQ:ARAY) A Risky Investment?
Feb 03Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge
Aug 17These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively
Apr 13The Return Trends At Accuray (NASDAQ:ARAY) Look Promising
Mar 14Shareholder Returns
| ARAY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -17.0% | 1.7% | -2.0% |
| 1Y | -45.6% | -0.6% | 12.1% |
Return vs Industry: ARAY underperformed the US Medical Equipment industry which returned -1% over the past year.
Return vs Market: ARAY underperformed the US Market which returned 12.3% over the past year.
Price Volatility
| ARAY volatility | |
|---|---|
| ARAY Average Weekly Movement | 10.6% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARAY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARAY's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 990 | Steve LaNeve | www.accuray.com |
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.
Accuray Incorporated Fundamentals Summary
| ARAY fundamental statistics | |
|---|---|
| Market cap | US$138.28m |
| Earnings (TTM) | -US$19.31m |
| Revenue (TTM) | US$450.90m |
Is ARAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARAY income statement (TTM) | |
|---|---|
| Revenue | US$450.90m |
| Cost of Revenue | US$311.46m |
| Gross Profit | US$139.45m |
| Other Expenses | US$158.76m |
| Earnings | -US$19.31m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 30.93% |
| Net Profit Margin | -4.28% |
| Debt/Equity Ratio | 226.6% |
How did ARAY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 14:01 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Accuray Incorporated is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Michael Gorman | BTIG |
| Lawrence Solow | CJS Securities, Inc. |